Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
The company reported free cash flow of Rs. 2,590 Mn for FY26
The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego
The platform combines internally developed technologies, strategic partnerships, and external AI capabilities
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Access to genomic testing, not therapy cost, is the biggest challenge
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
Subscribe To Our Newsletter & Stay Updated
